A dramatic epidemiological shift has occurred in HER2+ breast cancer. Due to highly effective adjuvant therapies preventing recurrence, the majority of new metastatic cases (two-thirds) are now de novo, a complete reversal from 15 years ago when relapsed disease dominated.

Beyond overall response rates, a critical area of excitement for new ADCs in lung cancer is their potential to treat brain metastases. Early data showing hints of intracranial efficacy is a significant point of interest, as this addresses a common and difficult-to-treat site of disease progression, offering a potential advantage over other therapies.

The study reveals a devastating and permanent financial outcome for CNS cancer survivors. Unlike other groups who may recover, they experience a sustained income reduction of over 25% a decade post-diagnosis. This is attributed to the severe, long-lasting late effects of treatment on their workability.

An expert argues the path to curing metastatic cancer may mirror pediatric ALL's history: combining all highly active drugs upfront. Instead of sequencing treatments after failure, the focus should be on powerful initial regimens that eradicate cancer, even if it means higher initial toxicity.

The GSK3 inhibitor was developed for CNS diseases, requiring high specificity and the ability to cross the blood-brain barrier. These same pharmaceutical characteristics—potency and lipophilicity—proved highly advantageous for treating cancer, demonstrating an unexpected but effective therapeutic pivot from neuroscience to oncology.

An increasing proportion of metastatic breast cancer is diagnosed de novo, not as a recurrence. This seemingly negative trend is actually a positive sign that adjuvant therapies are successfully curing more patients with early-stage disease.

With new CNS-active drugs dramatically improving survival after a brain metastasis diagnosis, some experts are now advocating for routine screening brain MRIs in high-risk patients. The goal is to detect asymptomatic lesions early, potentially preventing catastrophic neurologic events like seizures.

Glioblastoma isn't a single mass but has finger-like 'tentacles' (diffuse infiltration) extending into brain tissue. It is also genetically and cellularly diverse, meaning a single-pathway drug will inevitably miss many tumor cells, leading to rapid recurrence and treatment failure.

Unlike the intact blood-brain barrier, the blood-tumor barrier within brain metastases is permeable. This "leakiness" allows large molecules like the ADC trastuzumab deruxtecan (TDXD) to enter and deliver its payload, providing a mechanism for its high CNS efficacy.